🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Prospective cohort BACH-VTE study results are out. High rates of clinically-relevant bleeding and, unfortunately, poor performances of bleeding prediction scores (HAS-BLED, RIETE, VTE-BLEED snd VTE-PREDICT) in patients on anticoagulation for VTE👇#ISTH2024 Cihan Ay

Dr. Deborah Siegal reported the results of the VVIRTUOSO prospective cohort study. Symptomatic VTE is rare following hospitalization with COVID infection (0.9% (0.3-2.18 at 90 days)) and below threshold to evaluate thromboprophylaxis #ISTH2024 CanVECTOR Network Thrombosis Canada INVENT-VTE

Low dose colchicine could target inflammation in VTE, reduce PTS without increasing bleeding🩸! Stay tune for the CONQUEROR DVT pilot trial (double blind, placebo controlled RTC in pts with first LE proximal DVT) proposed by Nicola Potere Marc Carrier #ISTH2024

A great SOA talk by Dr. Geoff Barnes at #ISTH2024 on new anti-thrombotic agents, especially FXI inhibitors with ongoing active phase III studies which we look forward for more results in the coming years!

One dose of LMWH or UFH in the OR may be associated with a non-significant improved DFS at 3 years, shown in the new post-hoc analysis of PERI-OP 01 trial authors.elsevier.com/c/1jgDr_17tKVJ… Marc Carrier Ottawa Methods Centre

Safety of outpatient management of cancer-associated pulmonary embolism: a retrospective study | Haematologica haematologica.org/article/view/h… Hot off the press! Our experience in outpatient management of symptomatic cancer-associated PE. A big thank you to co-authors. More to come!

Join us in Toronto for Thrombosis Care in 2024: Meeting Today's Challenges. Come for the education and enjoy the city while you are there. Register today at bit.ly/3AeeK9b Marc Carrier Deborah Siegal Tzu-Fei Wang Eddy Lang

CanVECTOR 2024 Annual Conference: Less than One Month Away! Hotel Discounted Rates, Therapy Dogs, Top-3 Rated Abstracts, and More! Register Today - mailchi.mp/81acef14b9ac/y…

We don't want you to miss this great learning and networking opportunity. Join us for our annual conference. Register today: bit.ly/3AeeK9b #Thrombosis #MedEd

Do you struggle with whether to use anticoagulation for tumor thrombus? Hui et al. showed that patients with tumor thrombus have high risks of VTE, bleeding and mortality, and unfortunately the role of anticoagulation remains unclear. Tzu-Fei Wang Marc Carrier Read more at

ASH Late Breaking Abstract: Should patients receive extended duration anticoagulation with reduced or full dose DOAC for the secondary prevention of recurrent VTE - The RENOVE RCT presented by Francis Couturaud Reduced dose DOAC was not non inferior to full dose ((5-year

Interesting results with abelacimab in patients with AF NEJM 👇 Can uncoupling hemostasis and thrombosis by blocking FXI also help address unmet need in cancer-associated thrombosis? Can't wait for the results of the ASTER and MAGNOLIA trials! nejm.org/doi/full/10.10… @Anthos_Tx

Anticoagulant-related bleeding: 30-day incidence of mortality was 19.4% in patients with solid tumors. ICH alone increased risk of mortality 6-fold and GI bleeding 3-fold. Prediction of these adverse events could improve survival. #Hematology #Oncology doi.org/10.1002/ajh.27…

One of the best thrombosis programs in the world Marc Carrier Deborah Siegal Tzu-Fei Wang Université d'Ottawa | University of Ottawa

Terrific and provocative data from Moik et al/Cihan Ay Vienna CATS group showing how starting ICI tx can lead to CRP rise/drop. CRP rise strongly associated with cancer-VTE. Important implications for understanding the pro-inflammatory state induced by ICI therapy

Alok Khorana, MD I would also like to refer to the informative editorial comment written by Tzu-Fei Wang giving a good overview and discussion of the topic. sciencedirect.com/science/articl…

The RENOVE trial found that while low-dose DOACs did not meet non-inferiority for preventing recurrent VTE, it showed a better risk-benefit ratio, with less clinically relevant bleeding. Dose reduction may be a good option for many patients! thelancet.com/journals/lance… Francis Couturaud

Post-hoc analysis of the Hokusai VTE Cancer trial showed that treatment for recurrent VTE on AC were heterogeneous, and there were high risks of second recurrent VTE (9%) and major bleeding (10%) within 3 months! doi.org/10.1016/j.jtha… JTH Gary Raskob Marc Carrier

Prof. Mahé Isabelle presents API-CAT at #ACC2025, published in NEJM Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose for preventing recurrent VTE, with less clinically relevant bleeding 🩸in patients with cancer. nejm.org/doi/full/10.10…

Only one week to go for the Ottawa Race Weekend and the Desjardins Charity Challenge. The Thrombosis Canada team is closing in on their goal of reaching last year's total. Every donation will help to get them closer. Please consider donating at justgiving.com/team/thrombosi… and be part